Anti-CCR8 Monoclonal Antibody ZL-1218

Preferred Label : Anti-CCR8 Monoclonal Antibody ZL-1218;

NCIt definition : A humanized immunoglobulin G1 (IgG1) monoclonal antibody against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR8 monoclonal antibody ZL-1218 targets and binds to CCR8 on CCR8-positive tumor-infiltrating regulatory T-cells (Tregs) in the tumor microenvironment (TME), and depletes CCR8-positive tumor-infiltrating Tregs via antibody-dependent cellular cytotoxicity (ADCC). This may reactivate antitumor immune responses. CCR8 is specifically expressed by tumor-infiltrating Tregs in multiple types of cancer and plays a key role in immunosuppression.;

Molecule name : ZL 1218; ZL-1218;

NCI Metathesaurus CUI : CL1907334;

Détails

Origin ID

C200059;

UMLS CUI

C5854466;

Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- C-C Chemokine Receptor Type 8 [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients